WO2000032794A3 - Chlamydia antigens and corresponding dna fragments and uses thereof - Google Patents

Chlamydia antigens and corresponding dna fragments and uses thereof Download PDF

Info

Publication number
WO2000032794A3
WO2000032794A3 PCT/CA1999/001147 CA9901147W WO0032794A3 WO 2000032794 A3 WO2000032794 A3 WO 2000032794A3 CA 9901147 W CA9901147 W CA 9901147W WO 0032794 A3 WO0032794 A3 WO 0032794A3
Authority
WO
WIPO (PCT)
Prior art keywords
seq
nos
dna fragments
corresponding dna
chlamydia antigens
Prior art date
Application number
PCT/CA1999/001147
Other languages
French (fr)
Other versions
WO2000032794A2 (en
Inventor
Andrew D Murdin
Raymond P Oomen
Joe Wang
Original Assignee
Aventis Pasteur
Andrew D Murdin
Raymond P Oomen
Joe Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur, Andrew D Murdin, Raymond P Oomen, Joe Wang filed Critical Aventis Pasteur
Priority to JP2000585425A priority Critical patent/JP2002531095A/en
Priority to NZ512308A priority patent/NZ512308A/en
Priority to EP99957785A priority patent/EP1135509A2/en
Priority to CA002352759A priority patent/CA2352759A1/en
Priority to AU15405/00A priority patent/AU1540500A/en
Publication of WO2000032794A2 publication Critical patent/WO2000032794A2/en
Publication of WO2000032794A3 publication Critical patent/WO2000032794A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides purified and isolated polynucleotide molecules that encode Chlamydia polypeptides which can be used in methods to prevent, treat, and diagnose Chlamydia infection. In one form of the invention, the polynucleotide molecules are selected from DNA that encode polypeptides CPN100634 (SEQ ID Nos: 1, 2 and 11), CPN100635 (SEQ ID Nos: 3, 4, 12 and 13), CPN100638 (SEQ ID Nos: 5, 6 and 14), CPN100639 (SEQ ID Nos: 7, 8 and 15), CPN100708 (SEQ ID Nos: 9, 10 and 16).
PCT/CA1999/001147 1998-12-01 1999-12-01 Chlamydia antigens and corresponding dna fragments and uses thereof WO2000032794A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2000585425A JP2002531095A (en) 1998-12-01 1999-12-01 Chlamydia antigens and corresponding DNA fragments and uses thereof
NZ512308A NZ512308A (en) 1998-12-01 1999-12-01 Chlamydia antigens and corresponding DNA fragments and uses thereof
EP99957785A EP1135509A2 (en) 1998-12-01 1999-12-01 Chlamydia antigens and corresponding dna fragments and uses thereof
CA002352759A CA2352759A1 (en) 1998-12-01 1999-12-01 Chlamydia antigens and corresponding dna fragments and uses thereof
AU15405/00A AU1540500A (en) 1998-12-01 1999-12-01 (chlamydia) antigens and corresponding dna fragments and uses thereof

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US11043898P 1998-12-01 1998-12-01
US11034098P 1998-12-01 1998-12-01
US11042798P 1998-12-01 1998-12-01
US11042898P 1998-12-01 1998-12-01
US11033998P 1998-12-01 1998-12-01
US60/110,339 1998-12-01
US60/110,340 1998-12-01
US60/110,427 1998-12-01
US60/110,438 1998-12-01
US60/110,428 1998-12-01

Publications (2)

Publication Number Publication Date
WO2000032794A2 WO2000032794A2 (en) 2000-06-08
WO2000032794A3 true WO2000032794A3 (en) 2000-11-09

Family

ID=27537275

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/001147 WO2000032794A2 (en) 1998-12-01 1999-12-01 Chlamydia antigens and corresponding dna fragments and uses thereof

Country Status (6)

Country Link
EP (1) EP1135509A2 (en)
JP (1) JP2002531095A (en)
AU (1) AU1540500A (en)
CA (1) CA2352759A1 (en)
NZ (1) NZ512308A (en)
WO (1) WO2000032794A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807802B2 (en) 2002-11-12 2010-10-05 Abbott Lab Polynucleotides for the amplification and detection of Chlamydia trachomatis and Neisseria gonorrhoeae
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998058953A2 (en) * 1997-06-23 1998-12-30 Svend Birkelund Surface exposed proteins from chlamydia pneumoniae
WO1999027105A2 (en) * 1997-11-21 1999-06-03 Genset Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998058953A2 (en) * 1997-06-23 1998-12-30 Svend Birkelund Surface exposed proteins from chlamydia pneumoniae
WO1999027105A2 (en) * 1997-11-21 1999-06-03 Genset Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 1 November 1998 (1998-11-01), KNUDSEN, K.: "Identification of two novel genes encoding outer membrane complex associated surface layer proteins in Chlamydia pneumoniae", XP002132125 *
ILJIMA, Y.: "Characterization of Chlamydia pneumoniae species-specific proteins immunodominant in humans", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 32, no. 3, March 1994 (1994-03-01), pages 583-588, XP000881638 *
PEREZ MELGOSA M ET AL: "OUTER MEMBRANE COMPLEX PROTEINS OF CHLAMYDIA PNEUMONIAE", FEMS MICROBIOLOGY LETTERS,NL,AMSTERDAM, vol. 112, no. 2, 1 September 1993 (1993-09-01), pages 199 - 204, XP002057607, ISSN: 0378-1097 *
WIEDMANN-AL-AHMAD, M.: "Reactions of polyclonal and neutralizing anti-p54 monoclonal antibodies with an isolated, species-specific 54-kilodalton protein of Chlamydia pneumoniae", CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, vol. 4, no. 6, November 1997 (1997-11-01), pages 700-704, XP002132124 *

Also Published As

Publication number Publication date
JP2002531095A (en) 2002-09-24
WO2000032794A2 (en) 2000-06-08
CA2352759A1 (en) 2000-06-08
AU1540500A (en) 2000-06-19
EP1135509A2 (en) 2001-09-26
NZ512308A (en) 2004-01-30

Similar Documents

Publication Publication Date Title
EP1005540A4 (en) Ikk-beta proteins, nucleic acids and methods
MXPA03002413A (en) B7-like molecules and uses thereof.
AU4778101A (en) Novel polypeptides, and nucleic acids encoding the same
WO1994001548A3 (en) Human nucleic acid fragments, isolated from brain adrenal tissue, placenta or bone narrow
WO2001092308A3 (en) Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
IL140937A0 (en) Molecules designated ldcam
WO1998018932A3 (en) Novel pesticidal toxins and nucleotide sequences which encode these toxins
AU8881201A (en) Tnf receptor-like molecules and uses thereof
WO1998006841A3 (en) Two human nsp-like proteins
WO2002040668A3 (en) Proteins and dna sequences underlying these proteins used for treating inflammations
WO2002030973A8 (en) The caveolin-1 gene and polypeptide encoded thereby and methods of use thereof
CA2294566A1 (en) Ikk-.alpha. proteins, nucleic acids and methods
WO1998031795A3 (en) Novel human metallothionein
WO2000024765A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO1998011234A3 (en) Human protein kinases
WO2001042474A3 (en) Interferon-like molecules and uses thereof
WO1998025956A3 (en) Human GTP-binding proteins
MXPA03000979A (en) C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF.
WO2003008441A3 (en) Moringa seed proteins
WO2000032794A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO2001059120A3 (en) Il-17 like molecules and uses thereof
WO2002028889A3 (en) Haemophilus influenzae antigens and corresponding dna fragments
WO1998024896A3 (en) Muteins of obese protein
WO2003044047A3 (en) Virulence proteins of the genus yersinia and uses thereof
WO2001070808A3 (en) Angiogenesis - associated proteins, and nucleic acids encoding the same

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2000 15405

Country of ref document: AU

Kind code of ref document: A

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Kind code of ref document: A

Ref document number: 2352759

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2000 585425

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/005617

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 15405/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 512308

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1999957785

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09857128

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999957785

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999957785

Country of ref document: EP